Pricing Log in Create free account
Saturday 7 November 2026 Export MBIO’s income statement to Excel — free account

Mustang Bio, Inc.

MBIO Healthcare Biotechnology

EPS
+15.8%
Free cash flow
+27.8%

Quarter to June 2026, against a year earlier

0.39 0.00 0.00%
Market cap
$3.0M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.00
Sold, $m 0.00
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 1 — — — — — — — — — — —
Sell 2 — — — — — — — — — — —
Insider Ownership 4.35%

Capital & Financial Ratios $m

Size
Market Cap 2.99
Revenue ttm —
Net income ttm (3.03)
Free cash flow ttm (4.51)
Net debt Q (15.15)
Valuation
P/E 0.00
Forward P/E —
Price / sales 0.00
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.35
Financial health
Current ratio Q 1.97 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (254.25)
Growth
Revenue growth Q —
Operating income growth Q −32.20% (below 0%: shrinking)
EPS, this year +86.50% (at or above 15%: strong)
EPS, next year A +56.79% (at or above 15%: strong)
Revenue, next year A —
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

P/B against its own 10 years 0.73%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 6 7 17 15
Receivables 4 0 0 0
Inventory — — — —
Other — 1 — —
11 9 18 16
2023 2024 2025 Q'26
Payables 14 9 5 5
ST’ Debt — — — —
Other — — — —
15 13 8 8

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value 0.00% (37.31%) (40.95%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY24 Estimate −6.50 Actual −2.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY23 −94.00 −61.50 Beat by 32.50
Q4 FY23 −84.00 −35.50 Beat by 48.50
Q2 FY24 −7.00 −12.00 Miss by 5.00
Q3 FY24 −6.50 −2.00 Beat by 4.50

EPS $

Mar Jun Sep Dec Year
’26 (0.14) (0.16) — — —
’25 (0.05) (0.19) (0.07) (0.08) (0.39)
’24 (23.00) (17.50) (2.00) (8.23) (25.82)
’23 (103.00) (100.00) (61.50) (43.04) (300.00)
’22 (149.92) (142.43) (134.93) (134.93) (504.50)
’21 (142.43) (119.94) (142.43) (164.92) (569.71)
’20 (209.89) (239.88) (172.41) (239.88) (854.57)
Fiscal quarters ending in the months shown.

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (1) (1) (1) (2) (5)
’24 (5) (2) (2) (2) (11)
’23 (18) (12) (12) (7) (49)
’22 (16) (18) (16) (15) (65)
’21 (16) (12) (11) (15) (54)
’20 (10) (8) (10) (9) (37)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 0 (1) (1) (2) (4)
’24 (5) (2) (2) (2) (11)
’23 (18) (12) (6) (7) (44)
’22 (18) (18) (17) (16) (68)
’21 (16) (15) (12) (16) (59)
’20 (11) (8) (12) (11) (42)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — — — — — — —
Gross margin, % — 0.00 0.00 0.00 0.00 0.00 0.00 — — — 0.00 0.0 pt
EBT (13) (31) (31) (46) (60) (66) (78) (52) (16) (2) (3) (18.9%)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
Net income (13) (31) (31) (46) (60) (66) (78) (52) (16) (2) (3) (18.9%)
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Earnings (860.23) (929.53) (854.57) (967.02) (854.57) (569.71) (504.50) (300.00) (25.82) (0.39) (0.45) (57.5%)
Cash flow (280.88) (384.21) (536.04) (698.15) (531.61) (457.91) (423.33) (287.66) (18.70) (1.07) (0.67) (46.1%)
Capex 0.00 (83.06) (221.31) (76.82) (62.85) (45.78) (19.21) 34.22 0.00 0.24 0.00 n/m
Free cash flow (280.88) (467.27) (757.35) (774.97) (594.46) (503.69) (442.54) (253.44) (18.70) (0.84) (0.67) (47.6%)
Book value 1,651.43 1,775.43 1,013.82 1,073.85 1,402.21 959.04 301.06 0.72 (6.35) 1.94 1.12 (52.7%)
Shares, m 0 0 0 0 0 0 0 0 1 5 6 +90.7%
Valuation, ×
Valuation, × P/E — — — — — — — — — — 0 —
P/S — — — — — — — — — — 0 —
P/B — — — — — — — — — — 0 —
EV/Sales — — — — — — — — — — 0 —
EV/FCF — — — — — — — — — — 0 —
Cash, $m
Cash, $m Operating cash flow (4) (13) (19) (34) (37) (54) (65) (49) (11) (5) (5) +2.7%
Capex — (3) (8) (4) (4) (5) (3) 6 0 1 1 n/m
Free cash flow (4) (16) (27) (37) (42) (59) (68) (44) (11) (4) (5) (0.1%)
Balance, $m
Balance, $m Working capital 24 58 30 55 90 101 64 (4) (4) 10 8 (9.7%)
Net debt (27) (61) (34) (48) (96) (108) (48) (6) (7) (17) (15) (4.9%)
Shareholders’ equity 24 60 36 52 98 112 46 0 (4) 10 8 (9.9%)
Returns, %
Returns, % ROA (92.03) (68.77) (57.72) (79.84) (65.47) (56.47) (71.26) (93.68) (116.47) (14.28) (21.17) +77.8 pt
ROIC 0.00 0.00 (840.05) (781.85) (1,375.58) (933.55) 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (125.62) (74.40) (63.73) (105.37) (79.97) (62.96) (97.72) (222.44) 840.11 (67.93) (58.12) +57.7 pt
People
People Employees 3 6 38 51 62 102 113 80 6 4 — +3.2%
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fundamentals updated 26 Oct 2026

Mustang Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SXTP 60 Degrees Pharmaceuticals Inc. $3.2M — (loss-making) — (loss-making) −32.48% (below 0%: shrinking) n/m −54.33% (below 0%: shrinking) 27.32% (1,092.40%) Compare
ADXN Addex Therapeutics Ltd. Sponsored ADR $3.1M — (loss-making) — (loss-making) −85.95% (below 0%: shrinking) n/m −2.73% (below 0%: shrinking) (2.67%) 0.00% Compare
MBIO Mustang Bio, Inc. $3.0M — (loss-making) — — n/m +27.78% (above 0%: growing) 0.00% 0.00%
ERNA Ernexa Therapeutics Inc. $3.0M — (loss-making) — (loss-making) −94.12% (below 0%: shrinking) n/m −64.10% (below 0%: shrinking) 100.00% 0.00% Compare
CMND Clearmind Medicine Inc. $3.0M — (loss-making) — — n/m −77.94% (below 0%: shrinking) 0.00% 0.00% Compare
KALA KALA BIO, Inc. $3.0M — (loss-making) — (loss-making) −86.31% (below 0%: shrinking) n/m +80.19% (above 0%: growing) 0.00% 0.00% Compare
BCAB BioAtla, Inc. $2.9M — (loss-making) — (loss-making) +4,233.33% (above 0%: growing) n/m +97.03% (above 0%: growing) 100.00% 3.49% Compare
JUNS Jupiter Neurosciences, Inc. $2.8M — (loss-making) — — n/m −177.06% (below 0%: shrinking) 87.19% (11,334.30%) Compare
AFMDQ Affimed N.V. $2.8M — (loss-making) — (loss-making) −92.02% (below 0%: shrinking) n/m +46.95% (above 0%: growing) 100.00% (9,216.90%) Compare
Median of peers $3.0M — — −86.13% — −28.53% 57.26% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 3 December 2025

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 498.04k 487.21k 2.99
2023 514.48k 426.92k 22.79
2022 636.09k 417.05k 23.79
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Mustang Bio, Inc. (MBIO) Latest News

7 Jul

Impact 4 · · GlobeNewswire

5 Mar

Impact 3 · · GlobeNewswire

27 Feb

Impact 4 · · GlobeNewswire

11 Feb

Impact 3 · · GlobeNewswire

10 Feb

Impact 3 · · GlobeNewswire

6 Feb

Impact 3 ·

14 Jan

Impact 3 · · GlobeNewswire

8 Nov

Impact 4 · · pharmaceutical-technology.com

7 Nov

Impact 4 ·

26 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · TipRanks
Impact 3 · · GlobeNewswire

24 Oct

Impact 3 · · GlobeNewswire

28 Jun

Impact 4 · · GlobeNewswire

21 Jun

Impact 3 · · GlobeNewswire

20 Jun

Impact 3 · · GlobeNewswire

18 Jun

Impact 4 · · Zacks

17 Jun

Impact 4 · · GlobeNewswire

2 May

Impact 4 · · GlobeNewswire

29 Apr

Impact 4 · · GlobeNewswire

28 Mar

Impact 4 · · GlobeNewswire

11 Mar

Impact 4 · · GlobeNewswire

7 Mar

Impact 4 · · GlobeNewswire

11 Jan

Impact 3 · · GlobeNewswire

11 Dec

Impact 4 · · GlobeNewswire

14 Nov

Impact 4 · · GlobeNewswire

2 Nov

Impact 4 · · GlobeNewswire

30 Oct

Impact 3 · · GlobeNewswire

16 Aug

Impact 4 · · GlobeNewswire

14 Aug

Impact 4 · · GlobeNewswire
stockrow.com/MBIO · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com